BR112018003238A2 - seleção de pacientes para terapia de combinação - Google Patents

seleção de pacientes para terapia de combinação

Info

Publication number
BR112018003238A2
BR112018003238A2 BR112018003238A BR112018003238A BR112018003238A2 BR 112018003238 A2 BR112018003238 A2 BR 112018003238A2 BR 112018003238 A BR112018003238 A BR 112018003238A BR 112018003238 A BR112018003238 A BR 112018003238A BR 112018003238 A2 BR112018003238 A2 BR 112018003238A2
Authority
BR
Brazil
Prior art keywords
combination therapy
patient selection
entinostat
methods
therapeutic
Prior art date
Application number
BR112018003238A
Other languages
English (en)
Inventor
Ordentlich Peter
Original Assignee
Syndax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc
Publication of BR112018003238A2 publication Critical patent/BR112018003238A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

a presente invenção refere-se aos métodos para selecionar pacientes com câncer para tratamento com uma terapia de combinação compreendendo entinostat e um segundo agente terapêutico. em particular, são fornecidos métodos para o exame de um tipo de célula não cancerígena, células supressoras derivadas de mieloides, por exemplo, aquelas que são cd14-positivas e hla-dr-(baixo/negativas), como um indicador terapêutico no cenário de terapias de combinação com entinostat.
BR112018003238A 2015-09-02 2016-09-02 seleção de pacientes para terapia de combinação BR112018003238A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562213288P 2015-09-02 2015-09-02
US201562219612P 2015-09-16 2015-09-16
PCT/US2016/050274 WO2017041043A1 (en) 2015-09-02 2016-09-02 Selection of patients for combination therapy

Publications (1)

Publication Number Publication Date
BR112018003238A2 true BR112018003238A2 (pt) 2018-09-25

Family

ID=58188549

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018003238A BR112018003238A2 (pt) 2015-09-02 2016-09-02 seleção de pacientes para terapia de combinação

Country Status (14)

Country Link
US (2) US11397184B2 (pt)
EP (1) EP3345002A4 (pt)
JP (2) JP2018527570A (pt)
KR (2) KR102631377B1 (pt)
CN (2) CN108139403B (pt)
AU (2) AU2016318136B2 (pt)
BR (1) BR112018003238A2 (pt)
CA (1) CA2994731C (pt)
HK (1) HK1258128A1 (pt)
IL (1) IL257355B (pt)
MX (1) MX2018002640A (pt)
RU (1) RU2018111407A (pt)
WO (1) WO2017041043A1 (pt)
ZA (1) ZA201800931B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL254529B2 (en) * 2015-03-20 2024-05-01 Syndax Pharmaceuticals Inc A combination of a histone deacetylase inhibitor and an antibody against programmed cell death protein 1 for the treatment of cancer
CA3013047A1 (en) 2016-01-28 2017-08-03 Indiana University Research & Technology Corporation Use of histone deacetylase inhibitors for enhancing immunotherapies
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
JP7399883B2 (ja) * 2018-05-07 2023-12-18 シンダックス ファーマシューティカルズ， インコーポレイテッド 併用療法のための患者の選択
CN109251891B (zh) * 2018-09-21 2021-10-22 苏州大学附属第一医院 一种cd40联合pd-l1及细胞因子扩增pbmc的方法
CN117054649A (zh) * 2023-08-04 2023-11-14 广州中医药大学第一附属医院 一种慢性萎缩性胃炎向胃癌转化标志物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUD20080058A1 (it) * 2008-03-18 2009-09-19 Thankstem S R L Kit per la raccolta di sangue, preferibilmente periferico, per la produzione di cellule staminali
GB201015765D0 (en) * 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
CN103608028A (zh) * 2011-04-28 2014-02-26 南加利福尼亚大学 人类髓源抑制性细胞癌症标记
EA201201474A1 (ru) * 2011-09-02 2013-08-30 Синдэкс Фармасьютикалс, Инк. Способы лечения рака молочной железы
CA2878815A1 (en) * 2012-07-10 2014-01-16 Dana-Farber Cancer Institue, Inc. Anti-proliferative compounds and uses thereof
US20140205669A1 (en) * 2012-11-29 2014-07-24 The Penn State Research Foundation dhS1P AND USE OF SAME AS AN ANTICANCER THERAPEUTIC AND IMMUNOMODULATOR
EP3169326B1 (en) 2014-07-15 2021-03-31 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
IL254529B2 (en) 2015-03-20 2024-05-01 Syndax Pharmaceuticals Inc A combination of a histone deacetylase inhibitor and an antibody against programmed cell death protein 1 for the treatment of cancer

Also Published As

Publication number Publication date
KR102631377B1 (ko) 2024-01-29
KR20180048703A (ko) 2018-05-10
CN108139403A (zh) 2018-06-08
CN116893262A (zh) 2023-10-17
EP3345002A4 (en) 2019-05-08
AU2016318136B2 (en) 2022-10-20
JP7206352B2 (ja) 2023-01-17
US11397184B2 (en) 2022-07-26
CN108139403B (zh) 2023-05-09
IL257355A (en) 2018-04-30
AU2016318136A1 (en) 2018-02-22
US20230061048A1 (en) 2023-03-02
ZA201800931B (en) 2023-12-20
HK1258128A1 (zh) 2019-11-08
CA2994731C (en) 2023-09-26
WO2017041043A1 (en) 2017-03-09
MX2018002640A (es) 2018-06-20
JP2022009460A (ja) 2022-01-14
AU2022246409A1 (en) 2022-11-03
CA2994731A1 (en) 2017-03-09
EP3345002A1 (en) 2018-07-11
KR20240017973A (ko) 2024-02-08
JP2018527570A (ja) 2018-09-20
IL257355B (en) 2021-10-31
US20180252721A1 (en) 2018-09-06
RU2018111407A (ru) 2019-10-03
RU2018111407A3 (pt) 2020-02-10

Similar Documents

Publication Publication Date Title
BR112018003238A2 (pt) seleção de pacientes para terapia de combinação
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
CO2018001524A2 (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estos
BR112017026709A2 (pt) tratamento e diagnóstico de câncer
SV2018005677A (es) Mutaciones puntuales en cancer resistente a trk y metodos relacionados con las mismas
CL2017000515A1 (es) Cd123 agentes enlazadores y su uso
BR112019021822A2 (pt) Terapia de combinação
DOP2017000094A (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa))
BR112017004349A2 (pt) terapia com gene de globina para o tratamento de hemoglobinopatias
BR112017010761A2 (pt) tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
BR112018008503A2 (pt) método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer
PE20180260A1 (es) Metodos y kits para tratar la depresion
BR112016003868A8 (pt) Método, aparelho, mídia de armazenamento não transitório, e, programa de computador
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
BR112018008390A2 (pt) composições e métodos para transdução tumoral
UY33956A (es) Anticuerpo del factor antitisular humano y sus usos para tratar cáncer
MX2020011415A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
BR112019001142A2 (pt) vírus vaccinia recombinante e uso do mesmo
BR112019007210A2 (pt) métodos e composições para o tratamento da doença de fabry
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
BR112016026545A8 (pt) eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama
MX2018000052A (es) Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas.

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]